BioArctic AB (LTS:0RV2)
kr 165.75 6.4 (4.02%) Market Cap: 14.65 Bil Enterprise Value: 14.16 Bil PE Ratio: 0 PB Ratio: 14.75 GF Score: 75/100

Q1 2019 BioArctic AB Earnings Call Transcript

May 09, 2019 / 07:30AM GMT
Release Date Price: kr74.7 (-0.30%)
Operator

Hello, and welcome to the BioArctic Q1 2019 Report. (Operator Instructions) Just to remind you, this conference call is being recorded.

Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Thank you so much, and I'm happy to be here today and present the interim report from January to March 2019, and I will share the presentation with our CFO, Jan Mattsson.

Next slide, please. So BioArctic, here we are on the dot com -- NASDAQ.com exchange, and that -- this is our disclaimer. Next slide, please.

So today, I will start with a summary of our great projects -- progress in the projects for 2018 and for the beginning of this year. And I think we have had a great projects in all 3 disease areas as well as with our technology platform in the blood-brain bio market.

I will start with Alzheimer's disease, where BAN2401 with our -- is our most advanced program. Last summer, we presented positive result

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot